ASK REDCHAT ANYTHING ABOUT HUMACYTE INC.
Humacyte Inc. (NASDAQ: HUMA)
Listen to this Section
$0.70
+0.0112
(
+1.62% )
5.2K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Human Acellular Vessel (HAV)DetailsDialysis access (AV access) |
Phase 3 |
| Humacyte Acellular Tissue Engineered Vessel (ATEV™)DetailsDialysis access (AV access) |
Phase 3 |
Market Data
|
| Open |
$0.70 |
| Previous Close |
$0.69 |
| Volume |
5.2K |
| Market Cap |
$187.05M |
| Day Range |
$0.70 - $0.71 |
| 52 Week Range |
$0.55 - $2.84 |
| Shares Outstanding |
269.64M |
| Change % |
+1.62% |
| Net Change |
▲ 0.0112 |
| Insider Ownership |
-0.25% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2021 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-11,429,032.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-08-21 |
Sale |
-570174.00 |
Dougan Brady W |
| 2023-08-21 |
Sale |
-570174.00 |
Ayabudge LLC |